Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
CD28 superagonists (CD28SAs) are potent T‐cell‐activating monoclonal antibodies (mAbs). In contrast to their benign behavior and marked therapeutic efficacy as activators of regulatory T (Treg) cells in preclinical rodent models, a phase I trial of the human CD28SA TGN1412 (now called TAB08) in 2006 resulted in a life‐threatening cytokine release syndrome (CRS). We studied TAB08‐mediated Treg‐cell activation in a recently developed in vitro system of human PBMCs, which also reproduces the CRS experienced by the healthy volunteers. We show that just as in rodents, CD28SAs are potent activators and expanders of Treg cells from healthy donors and rheumatoid arthritis patients, even under effective blockade of pro‐inflammatory cytokine release by a corticosteroid. Moreover, CD28SA titration identifies a dose range where pro‐inflammatory cytokine secretion from conventional T cells is absent while appreciable Treg‐cell activation is maintained. Finally, we report that low‐dose application of TAB08 to healthy volunteers results in dose‐dependent systemic release of the Treg‐cell signature cytokine IL‐10 in the absence of the pro‐inflammatory factors associated with the CRS of the 2006 TGN1412 study. These results demonstrate the potential of appropriately dosed CD28SA and corticosteroid comedication to mobilize human Treg cells for the treatment of autoimmune and inflammatory conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“lowering the concentration of TAB08 identified a dose range where proinflammatory cytokine release was absent but Treg activation was still observed [53].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“inclusion of methyl-prednisolone, a corticosteroid routinely used to fight episodes of CRS in the clinic, effectively suppressed an in vitro cytokine storm triggered by high CD28SA concentrations while leaving Treg activation and expansion partially intact [53].”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“scrutiny of the healthy volunteers 0 plasma revealed no detectable cytokines but one: the Treg signature cytokine IL-10, an important anti-inflammatory mediator which was transiently found at significant levels in the two groups receiving the highest doses of TAB08 (Fig. 3).”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“These observations were not only made with PBMC samples from healthy donors but also from cohorts of RA [53], MS, SLE, and psoriasis patients (unpublished).”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
In the citing paper
“The recently published [53] results were a relief: not only was the drug well tolerated at these doses”
From The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account (2016) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
Ehrenstein, M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D. A., & Mauri, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040165 · Cited by 1,252
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation
Tang, Q., & Bluestone, J. A. (2008) · Nature Immunology · doi:10.1038/ni1572 · Cited by 1,031
Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function
Furtado, G. C., de Lafaille, M. A. C., Kutchukhidze, N., & Lafaille, J. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020190 · Cited by 625
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T., & Thompson, C. B. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.12.4472 · Cited by 566
Thornton, A. M., Donovan, E. E., Piccirillo, C. A., & Shevach, E. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6519 · Cited by 560
Nie, H., Zheng, Y., Li, R., Guo, T. B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3085 · Cited by 515
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Cited by
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Weirather, J., Hofmann, U. D. W., Beyersdorf, N., Ramos, G. C., Vogel, B., Frey, A., Ertl, G., Kerkau, T., & Frantz, S. (2014) · Circulation Research · doi:10.1161/circresaha.115.303895 · Cited by 699
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Role of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
Hofmann, U., & Frantz, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.304072 · Cited by 296
“Meanwhile, a different, reduced-dose antibody application regimen proved to be safe and effective in humans.(105) Other”
BackgroundWu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Targeting co-stimulatory molecules in autoimmune disease
Edner, N. M., Carlesso, G., Rush, J. S., & Walker, L. S. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0081-9 · Cited by 228
CAR T cells for infection, autoimmunity and allotransplantation
Maldini, C. R., Ellis, G. I., & Riley, J. L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0042-2 · Cited by 229
Biological drug and drug delivery-mediated immunotherapy
Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.018 · Cited by 211
“The Tregs-targeted treatment includes adoptive Treg therapy acquired by exogenous Treg transplantation and expansion of intrinsic Tregs induced by stimulators including Liver kinase B1 246 , IL-2 247,248 , vitamin D 249 , and CD28 superagonist 250 .”
BackgroundCD28 co-stimulation in T-cell homeostasis: a recent perspective
Hünig, T., Beyersdorf, N., & Kerkau, T. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s61647 · Cited by 190
“In this system, it was shown that just like in rodents, application of low CD28SA concentrations results in the selective activation of Treg cells (Figure 4F).(95) This finding was verified in vivo in a new Phase I study employing very low doses of the drug, which led to the selective release of the Treg signature cyt…”
Self-citationNa, S., Mracsko, E. Z., Liesz, A., Hünig, T., & Veltkamp, R. C. (2014) · Stroke · doi:10.1161/strokeaha.114.007756 · Cited by 128
“inflammatory cytokine release in PBMC cultures from patients with rheumatoid arthritis.(34) The same study also showed that slow infusion of much lower doses (≤7 μg/kg) than used in the ill-fated HV trial of 2006 (bolus injection of 100 μg/kg)”
Self-citationUnderstanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
Gardner, D., Jeffery, L. E., & Sansom, D. M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12834 · Cited by 121
“However, recent studies have continued to explore this approach and indicate that selective Treg expansion is nonetheless possible with such an approach (60).”
BackgroundCytokines: The Good, the Bad, and the Deadly
Ramani, T., Auletta, C. S., Weinstock, D., Mounho-Zamora, B., Ryan, P. C., Salcedo, T. W., & Bannish, G. (2015) · International Journal of Toxicology · doi:10.1177/1091581815584918 · Cited by 127
“1 mg/kg]) in healthy humans was associated with the T-reg-cell cytokine IL-10, in the absence of other proinflammatory cytokines or adverse clinical events.(35) The authors suggest these data support a potential role for TAB08 in mobilizing T-reg cells for treatment of autoimmune and inflammatory conditions.”
BackgroundResultCo-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 110
“Early CD28 super-agonist trials were associated with serious toxicities and abandoned in phase I clinical trials [20, 21].”
BackgroundDrug Development of Therapeutic Monoclonal Antibodies
Mould, D. R., & Meibohm, B. (2016) · BioDrugs · doi:10.1007/s40259-016-0181-6 · Cited by 110
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 91
GITR+ regulatory T cells in the treatment of autoimmune diseases
Petrillo, M. G., Ronchetti, S., Ricci, E., Alunno, A., Gerli, R., Nocentini, G., & Riccardi, C. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.011 · Cited by 79
PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS: NEW STRATEGY, NEW TARGETS
Nasonov, E. L. (2017) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2017-409-419 · Cited by 68
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
Hussain, K., Hargreaves, C. E., Roghanian, A., Oldham, R. J., Chan, H. T. C., Mockridge, C. I., Chowdhury, F., Frendéus, B., Harper, K., Strefford, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-593061 · Cited by 61
Zeng, Z., Yu, K., Chen, L., Li, W., Xiao, H., & Huang, Z. (2016) · Journal of Immunology Research · doi:10.1155/2016/8493767 · Cited by 59
“Recently, Tabares et al. revealed that a low dose of CD28SA was effective in the treatment of autoimmune and inflammatory conditions without catastrophic effects in humans [9].”
The rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
Self-citationThe Role of Regulatory T Cells in Pulmonary Arterial Hypertension
Qiu, H., He, Y., Ouyang, F., Jiang, P., Guo, S., & Guo, Y. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.014201 · Cited by 49
“models of autoimmunity because of the potent capability for inducing Treg expansion and increasing Treg activity.(92) A”
BackgroundNovel Immunotherapeutic Avenues for Rheumatoid Arthritis
Semerano, L., Minichiello, É., Bessis, N., & Boissier, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.005 · Cited by 49
“[38] identified a dose range of TGN1412/TAB08 that activated Tregs without the production of proinflammatory cytokines from Teffs.”
BackgroundTGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model
Weißmüller, S., Kronhart, S., Kreuz, D., Schnierle, B. S., Kalinke, U., Kirberg, J., Hanschmann, K.-M. O., & Waibler, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149093 · Cited by 45
An emerging role of regulatory T-cells in cardiovascular repair and regeneration
Fung, T. H. W., Yang, Y., & Lui, K. O. (2020) · Theranostics · doi:10.7150/thno.47118 · Cited by 45
“At a low dose, CD28 superagonist has been shown to preferentially expand and activate Treg in vitro, without the release of pro-inflammatory cytokine release by conventional T cells, which was thought to be the reason behind the fatal cytokine release syndrome experienced by patients in an earlier trial of the same dr…”
BackgroundA Transendocytosis Perspective on the CD28/CTLA-4 Pathway
Soskic, B., Qureshi, O. S., Hou, T., & Sansom, D. M. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00004-2 · Cited by 45
Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells
He, X., Smeets, R. L., van Rijssen, E., Boots, A. M. H., Joosten, I., & Koenen, H. J. P. M. (2017) · Scientific Reports · doi:10.1038/srep43003 · Cited by 38
Role of receptor occupancy assays by flow cytometry in drug development
Stewart, J. J., Green, C. L., Jones, N., Liang, M., Xu, Y., Wilkins, D. E. C., Moulard, M., Czechowska, K., Lanham, D., McCloskey, T. W., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21355 · Cited by 38
“With new understanding of the biology and the pharmacology in association to the TGN1412 target new trials are now being conducted (47).”
BackgroundPrzybył, Ł., Ibrahim, T., Haase, N., Golić, M., Rugor, J., Luft, F. C., Bendix, I., Serdar, M., Wallukat, G., Staff, A. C., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04892 · Cited by 38
Self-citationEmerging Therapies for Rheumatoid Arthritis
Kalden, J. R. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0032-4 · Cited by 39
Leach, M. W., Clarke, D. O., Dudal, S., Han, C., Li, C., Yang, Z., Brennan, F. R., Bailey, W. J., Chen, Y., Deslandes, A., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2009 · Cited by 36
Badr, M., McFleder, R. L., Wu, J., Knörr, S., Koprich, J. B., Hünig, T., Brotchie, J. M., Volkmann, J., Lutz, M. B., & Ip, C. W. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02685-7 · Cited by 41
Self-citationA non-conserved amino acid variant regulates differential signalling between human and mouse CD28
Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03385-8 · Cited by 37
Manipulating CD4+ T Cell Pathways to Prevent Preeclampsia
Murray, E. J., Gumusoglu, S. B., Santillan, D. A., & Santillan, M. K. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.811417 · Cited by 36
“Recently, testing of anti-CD28 monoclonal antibodies (mAbs) has been studied in PAH as a Treg stimulator because CD28 is a potent Treg activator and decreases proinflammatory cytokine secretion (Tabares et al., 2014).”
BackgroundIbrahim, T., Przybył, Ł., Harmon, A. C., Amaral, L. M., Faulkner, J., Cornelius, D. C., Cunningham, M., Hünig, T., Herse, F., Wallukat, G., et al. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12724 · Cited by 33
Self-citationSchmidt, T., Willenborg, S., Hünig, T., Deeg, C. A., Sønderstrup, G., Hertl, M., & Eming, R. (2015) · Experimental Dermatology · doi:10.1111/exd.12919 · Cited by 31
Self-citationWegner, J., Hackenberg, S., Scholz, C. J., Chuvpilo, S. A., Tyrsin, D., Matskevich, A. A., Grigoleit, G. U., Stevanović, S., & Hünig, T. (2015) · Blood · doi:10.1182/blood-2015-01-622704 · Cited by 29
“An extreme case illustrating this phenomenon is the dramatic difference in the responses of tissue-resident vs peripheral blood mononuclear cell (PBMC)-derived human T cells to the CD28 superagonist TGN1412 (now called TAB08).(12) Although PBMC cultures fail to respond to thismonoclonal Ab (mAb) in soluble form,(13) i…”
BackgroundSelf-citationIckrath, P., Kleinsasser, N. H., Ding, X., Ginzkey, C., Beyersdorf, N., Hagen, R., Kerkau, T., & Hackenberg, S. (2017) · Allergy & Rhinology · doi:10.2500/ar.2017.8.0214 · Cited by 26
“Some investigators see an increase in Treg cells after glucocorticoid therapy.37 However, in contrast, de Paz et al.38 described interindividually different responses of Treg cells to glucocorticoids among different patients, and Tabares et al.39 showed Treg cells to be relatively resistant to the immunosuppressive ac…”
ResultTechnical pitfalls when collecting, cryopreserving, thawing, and stimulating human T-cells
Browne, D. J., Miller, C., & Doolan, D. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382192 · Cited by 37
How Biologics Have Changed the Drug Discovery Landscape
McGonigle, P. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080811 · Cited by 30
CD28: A New Drug Target for Immune Disease
Xia, S., Chen, Q., & Niu, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666191114102830 · Cited by 27
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Kim, H. J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0153 · Cited by 29
“Although an initial clinical trial of i.v.-administered human CD28SA, TGN1412, provoked a life-threatening cytokine storm response (70), differential control of Treg and Tcon may be possible usingmuch lower doses of CD28SA (71).”
BackgroundWin, S. J., Kühl, A. A., Sparwasser, T. D., Hünig, T., & Kamradt, T. (2015) · European Journal of Immunology · doi:10.1002/eji.201546104 · Cited by 22
Self-citationYang, Z., Wang, H., Salcedo, T. W., Suchard, S. J., Xie, J., Schneeweis, L. A., Fleener, C., Calore, J. D., Shi, R., Zhang, S. X. Y., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227249 · Cited by 19
CD28 between tolerance and autoimmunity: the side effects of animal models
Porciello, N., Kunkl, M., & Tuosto, L. (2018) · F1000Research · doi:10.12688/f1000research.14046.1 · Cited by 20
T Cells of Infants Are Mature, but Hyporeactive Due to Limited Ca2+ Influx
Schmiedeberg, K., Krause, H., Röhl, F., Hartig, R., Jorch, G., & Brunner-Weinzierl, M. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166633 · Cited by 22
Kenter, M. J. H., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12605 · Cited by 17
TCR signaling fuels Treg cell suppressor function
Zhu, J., & Shevach, E. M. (2014) · Nature Immunology · doi:10.1038/ni.3014 · Cited by 20
Jamal, M. E., & Shibli, F. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00136 · Cited by 16
Tabares, P., Berr, S., Langenhorst, D., Sawitzki, B., ten Berge, I. J. M., Tony, H., & Hünig, T. (2017) · European Journal of Immunology · doi:10.1002/eji.201747244 · Cited by 16
Self-citationLi, Q., He, Y., & Pan, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad511 · Cited by 19
“This is an example of how unpredictable effects occur despite a 500-fold reduction in dose from animal experiments to FIH trials [12].”
BackgroundEthical considerations and challenges in first-in-human research
Koonrungsesomboon, N., Laothavorn, J., & Karbwang, J. (2016) · Translational research · doi:10.1016/j.trsl.2016.05.006 · Cited by 22
Kaplan, A., Altara, R., Eid, A. H., Booz, G. W., & Zouein, F. A. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000436 · Cited by 15
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Schoenfeld, K., Harwardt, J., & Kolmar, H. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0329 · Cited by 13
New Trials in Lupus and where Are we Going
Thanou, A., & Merrill, J. T. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0745-1 · Cited by 13
Stimulatory and Inhibitory Co-signals in Autoimmunity
Okazaki, T., & Okazaki, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_8 · Cited by 12
Stabilizing Human Regulatory T Cells for Tolerance Inducing Immunotherapy
He, X., Koenen, H. J. P. M., Slaats, J., & Joosten, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0017 · Cited by 13
Gladow, N., Hollmann, C., Ramos, G. C., Frantz, S., Kerkau, T., Beyersdorf, N., & Hofmann, U. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227734 · Cited by 12
“[25, 26] conventional T-cell activation, as tested here, or superagonistic anti-CD28 mAbs which are boosting the Foxp3 T-cell compartment, have been tested in early clinical studies and proved to be save [27].”
BackgroundHuman-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Uehlein, S., Ding, X., Flößer, J., Schmidt, S., Steitz, J., Bille, M., Schnitter, F., Baltes, S., Saalmüller, A., Gerner, W., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100174 · Cited by 15
CD 28 signals the differential control of regulatory T cells and effector T cells
Mikami, N., & Sakaguchi, S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444513 · Cited by 13
“4 They found that a certain range within the TGN1412/TAB08 antibody dose activated Treg cells to proliferate but failed to induce Tconv cells to produce inflammatory cytokines at a toxic level [8].”
BackgroundResultInfluentialAlhosseini, M. N., Ebadi, P., Karimi, M. H., Migliorati, G., Cari, L., Nocentini, G., Heidari, M., & Soleimanian, S. (2024) · Transplant Immunology · doi:10.1016/j.trim.2024.102069 · Cited by 10
Nocentini, G., Cari, L., Migliorati, G., & Riccardi, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00016-7 · Cited by 9
Charles, J., Vrionis, A., Mansur, A., Mathias, T. J., Shaikh, J., Ciner, A., Jiang, Y., & Nezami, N. (2023) · Cancers · doi:10.3390/cancers15092624 · Cited by 8
“Immunotherapy surrounding CD28 to date has been generally unsuccessful, as early CD28 agonist trials were commonly abandoned in phase I due to severe toxicities and side effect profiles [175,176].”
BackgroundBeyersdorf, N., Werner, S., Wolf, N., Hünig, T., & Kerkau, T. (2015) · European Journal of Immunology · doi:10.1002/eji.201445317 · Cited by 8
Self-citationExperimental drug that injured UK volunteers resumes in human trials
Dyer, O. (2015) · BMJ · doi:10.1136/bmj.h1831 · Cited by 8
Iwata, Y., Harada, A., Hara, T., Kubo, C., Inoue, T., Tabo, M., Ploix, C. C., Manigold, T., Hinton, H. J., & Mishima, M. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.523 · Cited by 7
“The severity of CRS could be decreased by an appropriate dosage regimen (Hale et al., 2004; Tabares et al., 2014) or by medication with anti-inflammatory agents (Lee et al.”
BackgroundLangenhorst, D., Tabares, P., Gulde, T., Becklund, B. R., Berr, S., Surh, C. D., Beyersdorf, N., & Hünig, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01985 · Cited by 9
Self-citationCritical Aspects of Integrated Nonclinical Drug Development
Koch, E., & Plassmann, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00002-5 · Cited by 6
Enhancing human regulatory T cells in vitro for cell therapy applications
Milward, K. F., Wood, K. J., & Hester, J. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.012 · Cited by 8
Kalden, J. R. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0122-2 · Cited by 5
Orrù, V., Steri, M., Cucca, F., & Fiorillo, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714461 · Cited by 5
Found in translation – EJI gets a facelift
(2016) · European Journal of Immunology · doi:10.1002/eji.201670074 · Cited by 5
T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect
Wu, Y., Anasetti, C., & Yu, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00011-6 · Cited by 6
CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
Thaventhiran, T., Wong, W., Alghanem, A. F., Alhumeed, N., Aljasir, M. A., Ramsey, S. J., Sethu, S., Yeang, H. X. A., Chadwick, A. E., Cross, M. J., et al. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0042 · Cited by 3
Need for a proactive and structured approach to risk analysis when designing phase I trials
van den Bogert, C. A., & Cohen, A. F. (2015) · BMJ · doi:10.1136/bmj.h3899 · Cited by 3
Hematopoietic Stem Cell-Based Therapy for HIV Disease: A Role for Regulatory T Cells
Schaefer, J. B. P. K. R. K. K. (2015) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000300 · Cited by 2
“To assess activation requirements of contactdependent immune suppression by human nTreg cells different protocols e.g. with anti12 CD3/CD28 [55], CD28SA [55,67,68], or anti-CD3/CD2/CD28 were employed [64] in order to ameliorate GvHD underlying ability of these treatments to do bothexpansion and activation of nTreg cel…”
BackgroundMethodInfluentialZhengfei, L. I., Zhang, J., Zhang, R., & Kuang, Y. (2021) · Food Science and Technology · doi:10.1590/fst.10421 · Cited by 2
“Treg cells can secrete IL-10, which inhibits the release of TNF-α, IFN-γ and other pro-inflammatory factors (Tabares et al., 2014).”
Background[Progress in monoclonal antibody-based immunotherapy for cancer treatment].
Guo, Y. (2015) · PubMed · Cited by 2
Realizing the potential of agonistic antibody immunotherapy
Cragg, M. S., Yu, X., Paluch, C., & Davis, S. J. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01442-2 · Cited by 2
Considerations for the Preclinical Safety Evaluation of Biopharmaceuticals☆
Cavagnaro, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.01943-7 · Cited by 1
T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders
Brennan, F. R. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch32 · Cited by 1
CD28 Costimulation and Regulatory T Cells
Soskic, B., & Sansom, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.30078-5 · Cited by 2
Stadtmüller, A., Grampp, R., Schnitter, F., Becker, F., Nuriyeva, K., Langenhorst, D., Metka, L., Günther, K., Gladow, N., Hofmann, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.28.685145 · Cited by 1
“In humans, low-dose CD28-SA application with dosages up to 7 µg/ kg bw has been tested in healthy volunteers and was very well tolerated (28).”
CD28 Costimulation and Regulatory T Cells
Soskic, B., & Sansom, D. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30078-5
Lukka, P. B., Wagh, S., & Meibohm, B. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch9
Suzuki, Y., Matsuno, K., & Inano, A. (2020) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.51.1
MacGregor, H. L. (2020) · TSpace (University of Toronto)
Kostimulatorische und -inhibitorische Signale für T-Zellen
Rush‐Kittle, J., & Gámez-Díaz, L. Y. (2021) · Trillium Immunologie · doi:10.47184/ti.2021.01.01
Die Rolle des ko-stimulatorischen Moleküls CD28 in verschiedenen Phasen der EAE
Hufschmidt, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6671
Faculty Opinions recommendation of CD28 costimulation: from mechanism to therapy.
Tuosto, L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726363559.793546230
McGeachy, M. J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732850338.793546604
Leach, M. W., & Hammerman, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00024-5
Koch, E., & Plassmann, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00021-9
Badr, M., McFleder, R. L., Wu, J., Knörr, S., Koprich, J. B., Hünig, T., Brotchie, J. M., Volkmann, J., Lutz, M. B., & Ip, C. W. (2024) · Figshare · doi:10.6084/m9.figshare.26558666
Self-citationBadr, M., McFleder, R. L., Wu, J., Knörr, S., Koprich, J. B., Hünig, T., Brotchie, J. M., Volkmann, J., Lutz, M. B., & Ip, C. W. (2024) · Figshare · doi:10.6084/m9.figshare.26558663
Self-citationCD28 : nouvelles données sur un récepteur majeur de la costimulation lymphocytaire T
Morin, S. O. (2017) · theses.fr (ABES) · doi:10.70675/cb01635fz2f63z43e2zad0cz210485c4c5cf
Metadata
- Authors
- Tabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T.
- Affiliations
- University of Würzburg (DE)
- TheraMAB LLC Würzburg Germany
- TheraMAB LLC Moscow Russian Federation
- Universitätsklinikum Würzburg (DE)
- Corresponding author
- Hünig, Thomas
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2014-02
- Volume
- 44
- Issue
- 4
- Pages
- 1225-1236
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1570409954
- Cited by
- 97
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 8 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 16 · 2015: 17 · 2014: 11
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Immunology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB-TR52)
- TheraMab LLC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- regulatory T cells, TGN1412, cytokine release syndrome, low-dose immunotherapy, IL-10, rheumatoid arthritis, autoimmune disease therapy, dose titration, human peripheral blood mononuclear cells
- MeSH terms
- Adrenal Cortex Hormones, Arthritis, Rheumatoid, Cells, Cultured, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Leukocytes, Mononuclear, Lymphocyte Activation, Cytokines, Interleukin-10, CD28 Antigens, Inflammation Mediators, Cell Proliferation, T-Lymphocytes, Regulatory, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.